Pay in 4 interest-free payments of $5.70 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
DSIP Injections: Direct and Fast-Acting Now lets flip to the injectable side what that looks like, how it differs, and what it may offer
In a 48-week phase II clinical trial conducted on patients with type 2 diabetes and obesity, treatment with a dose of 10 mg/kg of bimagrumab resulted in a significant reduction in fat mass by 20.5% (compared to 0.5% in the placebo group), while lean body mass increased by 3.6% (as opposed to a decrease of 0.8% in the placebo group), leading to an overall body weight reduction of -6.5%, which was substantially better than the -0.8% observed in the placebo group
EFFECTIVENESS Tirzepatide has been studied in a trial of 2,539 patients who had obesity but not diabetes, with a BMI of more than 30 kg per m 2 or a BMI of more than 27 kg per m 2 plus at least one weight-related comorbid condition
added fibre and gut health claims
US$ 25.73
US$ 21.61
US$ 20.64
US$ 24.98
